Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Oraya Therapeutics

Request full access

Oraya Therapeutics International - Oraya TherapeuticsOraya Therapeutics

Newark, United StatesFounded 2007Biotechnology

About Oraya Therapeutics

Oraya Therapeutics, Inc., founded in 2007 and headquartered in Newark, California, was a medical technology company focused on developing non-invasive therapies for eye diseases, particularly wet age-related macular degeneration (wet AMD). The company was later acquired by Carl Zeiss Meditec. The company's leadership included President and CEO Jim Taylor, who brought over 30 years of experience from the medical device industry, having held leadership roles at Carl Zeiss Meditec and Coherent Medical. His personal experience with his mother's struggle with wet AMD fueled his involvement with Oraya, aiming to reduce the burden of frequent injections required by standard treatments.

The company's core offering was the Oraya Therapy™, delivered by the IRay® Radiotherapy System. This technology was developed to provide a one-time, non-invasive treatment for wet AMD as an adjunct to anti-VEGF injections, the standard of care. The procedure, which took about 20 minutes in an outpatient setting, used a low-voltage X-ray source combined with a robotic positioning system, laser guidance, and proprietary eye-stabilization technology to deliver a precise dose of radiation to the macula. The primary benefit for patients was the potential to maintain or improve vision while significantly reducing the number of required anti-VEGF injections, which are often costly and uncomfortable. The company's business model centered on the commercialization of the IRay system to hospitals and ophthalmology clinics.

Oraya Therapeutics achieved significant milestones, including receiving the European CE Mark for the IRay system in 2010, which permitted its commercialization in Europe. The company focused its initial commercial efforts on markets in Germany, the United Kingdom, and Switzerland. Clinical validation came from the INTREPID study, a sham-controlled trial that demonstrated the therapy's effectiveness in reducing anti-VEGF injection frequency by over 30%, with some patient groups seeing a reduction of up to 55%. The company successfully raised $113 million over nine funding rounds from investors including Scale Venture Partners, Domain Associates, Essex Woodlands Health Ventures, and Hercules Capital. In late 2014, Oraya entered a strategic collaboration with Carl Zeiss Meditec, which provided funding to accelerate its European growth in exchange for rights to a majority stake, ultimately leading to Oraya's assets being absorbed into Zeiss in 2016.

Source: Dealroom company data

At a glance

Status
Closed
Employees
12
Open positions
None listed
Sector
Hard Tech
Business model
Manufacturing
Client focus
B2B

Funding history

7 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
GRANT✓Other financing Aug 2014 $215K — Undisclosed —
SERIES D✓Equity / VC May 2014 $25M $100M Undisclosed —
Showing the latest 2 of 7 recorded eventsBook a demo for the full funding history →

Growth signals

Oraya Therapeutics website traffic

Latest recorded traffic for Oraya Therapeutics is 420 monthly website visits, down 10.6% over the last three months. Oraya Therapeutics's team declined 7.7% over the past year.

Latest monthly visits420 3-month web change-10.6% 1-year team growth-7.7%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Oraya Therapeutics in the Newark ecosystem

Live from Dealroom

The Oraya Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

7 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A3 investors entered at this stage

  • EW Healthcare Partners
  • Essex Woodlands Health Ventures
  • Synergy Life Science Partner

Series B and later2 investors entered at this stage

  • Domain Associates
  • Scale Venture Partners

Other known investors2 additional known investors

Team profiled 20 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 5 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Oraya Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Oraya Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.